Cancer Res Treat.  2020 Jul;52(3):680-688. 10.4143/crt.2019.351.

Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant

Affiliations
  • 1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
  • 2Department of Surgery, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 3Cancer Prevention Center, Yonsei Cancer Center, Seoul, Korea
  • 4Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
  • 5Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
  • 6Center for Breast Cancer, National Cancer Center, Goyang, Korea
  • 7Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
  • 8Breast Care Center, Seoul National University Bundang Hospital, Seongnam, Korea
  • 9Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 10Department of Surgery, Dankook University College of Medicine, Cheonan, Korea
  • 11Department of Surgery, School of Medicine, Kyungpook National University, Daegu, Korea
  • 12Division of Breast and Endocrine Surgery, Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
  • 13Department of Surgery, Breast Care Center, Daerim St. Mary's Hospital, Seoul, Korea

Abstract

Purpose
Recent studies revealed the BRCA1 c.5339T>C, p.Leu1780Pro variant (L1780P) is highly suggested as a likely pathogenic. The aim of this study was to evaluate clinicopathologic features of L1780P with breast cancer (BC) using multicenter data from Korea to reinforce the evidence as a pathogenic mutation and to compare L1780P and other BRCA1/2mutations using Korean Hereditary Breast Cancer (KOHBRA) study data.
Materials and Methods
The data of 54 BC patients with L1780P variant from 10 institutions were collected and the clinicopathologic characteristics of the patients were reviewed. The hereditary breast and/or ovarian cancer–related characteristics of the L1780P variant were compared to those of BC patients in the KOHBRA study.
Results
The median age of all patients was 38 years, and 75.9% of cases showed triple-negative breast cancer. Comparison of cases with L1780P to carriers from the KOHBRA study revealed that the L1780P patients group was more likely to have family history (FHx) of ovarian cancer (OC) (24.1% vs. 19.6% vs. 11.2%, p < 0.001 and p=0.001) and a personal history of OC (16.7% vs. 2.9% vs. 1.3%, p=0.003 and p=0.001) without significant difference in FHx of BC and bilateral BC. The cumulative risk of contralateral BC at 10 years after diagnosis was 31.9%, while the cumulative risk of OC at 50 years of age was 20.0%. Patients with L1780P showed similar features with BRCA1 carriers and showed higher penetrance of OC than patients with other BRCA1 mutations.
Conclusion
L1780P should be considered as a pathogenic mutation. Risk-reducing salpingo-oophorectomy is highly recommended for women with L1780P.

Keyword

Breast; Neoplasms; c.5339T>C; p.Leu1780Pro; Survival; Prognosis

Figure

  • Fig. 1. Schematic diagram of patient enrollment. BC, breast cancer; OC, ovarian cancer. a)Two institutions have no data of L1780P variant, b)Nine patients had breast and ovarian cancer.

  • Fig. 2. Recurrence-free survival (A) and event-free survival (B) curves of breast cancer patients with BRCA1 c.5339T>C (p.Leu1780Pro).

  • Fig. 3. Cumulative contralateral breast cancer (A) and cumulative ovarian cancer (B) incidence in patients with BRCA1 c.5339T>C (p.Leu1780Pro).


Reference

References

1. Lee EH, Park SK, Park B, Kim SW, Lee MH, Ahn SH, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 122:11–25.
Article
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72:1117–30.
Article
3. Tavtigian SV, Greenblatt MS, Goldgar DE, Boffetta P; IARC Unclassified Genetic Variants Working Group. Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Hum Mutat. 2008; 29:1261–4.
Article
4. Ryu JM, Kang G, Nam SJ, Kim SW, Yu J, Lee SK, et al. Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from 'unknown significance' to 'Likely pathogenic' based on clinical evidence in Korea. Breast. 2017; 33:109–16.
5. Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, et al. Identification of a novel BRCA1 pathogenic mutation in Korean patients following reclassification of BRCA1 and BRCA2 variants according to the ACMG standards and guidelines using relevant ethnic controls. Cancer Res Treat. 2017; 49:1012–21.
Article
6. Yoon KA, Park B, Lee BI, Yang MJ, Kong SY, Lee ES. Clinically significant unclassified variants in BRCA1 and BRCA2 genes among Korean breast cancer patients. Cancer Res Treat. 2017; 49:627–34.
Article
7. Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol. 2004; 22:1638–45.
Article
8. Jang JH, Lee JE, Kwon MJ, Ki CS, Kim JW, Nam SJ, et al. Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer: the importance of whole-gene sequencing. J Hum Genet. 2012; 57:212–5.
Article
9. Han SH, Lee KR, Lee DG, Kim BY, Lee KE, Chung WS. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet. 2006; 70:496–501.
Article
10. Park KS, Cho EY, Nam SJ, Ki CS, Kim JW. Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants. Genet Med. 2016; 18:1250–7.
Article
11. Han SA, Park SK, Ahn SH, Lee MH, Noh DY, Kim LS, et al. The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report. Clin Oncol (R Coll Radiol). 2011; 23:434–41.
Article
12. Ossa CA, Torres D. Founder and recurrent mutations in BRCA1 and BRCA2 genes in Latin American countries: state of the art and literature review. Oncologist. 2016; 21:832–9.
Article
13. Apostolou P, Pertesi M, Aleporou-Marinou V, Dimitrakakis C, Papadimitriou C, Razis E, et al. Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation. Clin Genet. 2017; 91:482–7.
14. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018; 39:593–620.
15. Ferla R, Calo V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol. 2007; 18 Suppl 6:vi93–8.
Article
16. Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002; 39:611–4.
Article
17. Choi MC, Jang JH, Jung SG, Park H, Joo WD, Song SH, et al. Unclassified variants of BRCA1 and BRCA2 in Korean patients with ovarian cancer. Int J Gynecol Cancer. 2018; 28:308–15.
Article
18. Lee J, Kim S, Kang E, Park S, Kim Z, Lee MH, et al. Influence of the Angelina Jolie announcement and insurance reimbursement on practice patterns for hereditary breast cancer. J Breast Cancer. 2017; 20:203–7.
Article
19. Kang E, Kim SW. The Korean Hereditary Breast Cancer study: review and future perspectives. J Breast Cancer. 2013; 16:245–53.
Article
20. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res. 2010; 70:4880–90.
Article
21. Rowling PJ, Cook R, Itzhaki LS. Toward classification of BRCA1 missense variants using a biophysical approach. J Biol Chem. 2010; 285:20080–7.
Article
22. So MK, Jeong TD, Lim W, Moon BI, Paik NS, Kim SC, et al. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines. Breast Cancer. 2019; 26:510–9.
Article
23. Lee JS, Oh S, Park SK, Lee MH, Lee JW, Kim SW, et al. Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort. J Med Genet. 2018; 55:794–802.
Article
24. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015; 313:1347–61.
25. Park JS, Lee ST, Han JW, Kim TI, Nam EJ, Park HS. Difference in risk of breast and ovarian cancer according to putative functional domain regions in Korean BRCA1/2 mutation carriers. Clin Breast Cancer. 2018; 18:362–73.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr